Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04772365 | A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects | PHASE1 | COMPLETED | 52 | — | — | Mar 1, 2021 | Dec 10, 2021 | Nov 29, 2022 | 1 | China |
Incidence and severity of adverse events
| Arm | Type | Description |
|---|---|---|
| Treatment group A | EXPERIMENTAL | - |
| Treatment group B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SHR-1819 | DRUG | SHR-1819 will be subcutaneously administered with different dose levels; |
| Placebo | DRUG | Placebo will be subcutaneously administered with different dose levels; |
Inclusion Criteria: 1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent. 2. Be able to comply with all the requirements and able to complete the study. 3. Male or female aged between 18 years and 55...